Company intelligence / Profile preview

PDI Therapeutics

La Jolla, California, United States

Ownership: Private
Development stage: Other

Overview

PDI Therapeutics developed CLN-619, a first-in-class monoclonal antibody targeting the MICA/NKG2D axis to enhance immune recognition and destruction of tumor cells. Preclinical data showed strong single-agent activity and a clean safety profile in non-human primates, with rationale for combination with checkpoint inhibitors. The asset was advanced to clinical development under Cullinan Oncology post-acquisition[4].

Therapeutic areas: Oncology
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

Collaboration with Cullinan Oncology to advance CLN-619 into clinical testingEarlier R&D collaboration with GlaxoSmithKline (GSK) as part of Avalon Ventures/COI Pharmaceuticals incubator

Beyond the preview

Go deeper on PDI Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PDI Therapeutics.

Explore the full profile